Thus, the management of respiratory diseases often involves treatments that directly affect tissue biomechanics. Bronchodilators, used extensively in COPD, relax airway smooth muscles, reducing resistance and improving airflow . However, prolonged use can lead to receptor desensitization, diminishing efficacy over time . Specific case studies illustrate the interactions between chemical transport mechanisms, biophysical disruptions and respiratory diseases. For example, the increased viscosity of mucus in cystic fibrosis impedes convection and diffusion . Similarly, in pulmonary fibrosis, the thickening of the alveolar walls restricts diffusion and compliance, leading to severe gas exchange impairments . Research indicates that in severe emphysema, therapeutic interventions like lung volume reduction surgery (LVRS) can mechanically stabilize the chest wall, improving lung function and patient outcomes . Despite significant advances, there remain gaps in understanding the full extent of these mechanisms in disease progression. The precise molecular pathways that govern the interaction between chemical species transport and lung biomechanics, and how these pathways could be therapeutic targets, require further investigation .